Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease

"Huntington’s disease (HD) is a neurological disorder that can impact an individual’s physical, mental and emotional functioning. About 90% of individuals with HD will develop chorea, the involuntary movements associated with HD, and we know its symptoms profoundly impact not only the individual, but also their family members and care partners.

New research presented at Advanced Therapeutics in Movement & Related Disorders (ATMRD) Congress highlights the significant impact of chorea on both those living with HD and their caregivers across various aspects of daily life including emotional and social wellbeing."

Learn more about these insights https://bit.ly/4dRUR9y